$RXII at breakout $1.328 Nasdaq GM Ultra low flo
Post# of 63692
Posted On: 11/17/2016 8:03:33 PM
$RXII at breakout $1.328
Nasdaq GM
Ultra low float
10-Q 11/10/16
Shares Outstanding 6.6M
Float 5.13M
% Held by Insiders N/A
% Held by Institutions N/A
Shares Short 57.12k
Short Ratio 1.1
Short % of Float 0.87%
Shares Short (prior month) 78.52k
RXi Pharmaceuticals Corporation, a clinical-stage RNAi company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and a Phase I/II clinical trial in retinal scarring. It is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, a formulation of diphenylcyclopropenone, which is in Phase II clinical trial for the treatment of various disorders, such as warts, alopecia areata, non-malignant skin tumors, and cutaneous metastases of melanoma. In addition, the company is developing dermal scarring and wart programs with its sd-rxRNA technology. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Nasdaq GM
Ultra low float
10-Q 11/10/16
Shares Outstanding 6.6M
Float 5.13M
% Held by Insiders N/A
% Held by Institutions N/A
Shares Short 57.12k
Short Ratio 1.1
Short % of Float 0.87%
Shares Short (prior month) 78.52k
RXi Pharmaceuticals Corporation, a clinical-stage RNAi company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and a Phase I/II clinical trial in retinal scarring. It is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, a formulation of diphenylcyclopropenone, which is in Phase II clinical trial for the treatment of various disorders, such as warts, alopecia areata, non-malignant skin tumors, and cutaneous metastases of melanoma. In addition, the company is developing dermal scarring and wart programs with its sd-rxRNA technology. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
(0)
(0)Scroll down for more posts ▼